Corvus Pharmaceuticals's total assets for Q3 2025 were $80.47M, a decrease of -10.05% from the previous quarter. CRVS total liabilities were $8.71M for the fiscal quarter, a -5.71% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.